Zimbabwe has turned down a major US healthcare agreement valued at $367m (272 million pounds) over five years over the United States' request for confidential biological samples.
The decision became public following a official document from December was disclosed, which showed Head of State Emmerson Mnangagwa believed the deal was "skewed".
A government representative has since clarified that the US was demanding access to health data for scientific study and profit but was not willing to guarantee the benefits from any future medical innovations.
"We will now turn to the challenging and unfortunate task of winding down our health assistance in Zimbabwe," remarked American envoy to Zimbabwe Pamela Tremont publicly.
Her embassy said the US had provided over $1.9bn as health assistance to Zimbabwe over the last twenty years.
A doctors' association in Zimbabwe has appealed for further talks to find a agreement agreeable to both sides so the country's vital HIV programme can be sustained.
Broader Context
Zimbabwe's decision follows a similar case in neighbouring Kenya, where a court halted a related health funding agreement following legal challenges were raised about the security of citizens' medical information.
After returning to office recently, US President Donald Trump has reduced foreign aid and closed the key foreign aid agency.
USAID had managed assistance for the American government, but Trump argued its spending was "wasteful" and his administration was pursuing government-to-government agreements to boost transparency and responsibility.
As per reports, Sixteen African countries have to date agreed to these new agreements, representing more than $18.3bn of fresh investment.
Specifics of the Declined Deal
The money for Zimbabwe was intended to supported "combating HIV/Aids, tuberculosis, malaria, maternal and child health, and disease outbreak preparedness.
"We believe this partnership might have yielded extraordinary benefits for the people of Zimbabwe, particularly the 1.2 million currently on HIV treatment via American-funded initiatives," the Ambassador added.
However, government spokesperson Nick Mangwana maintained the arrangement was "asymmetrical".
"Our nation was requested to provide its genetic material and health information for a long time, with no equivalent assurance of benefiting from any scientific breakthroughs – such as new medicines or tests – that could result from that shared data," he stated.
"In essence, our country would provide the basic resources for medical research without any assurance that the final treatments would be accessible to our population if a new health crisis arise."
National Interest and Global Health
Mangwana further noted that the American exit from the global health body and its pursuit of bilateral deals were upending systems previously set up through the global organization.
The spokesperson cited its Pathogen Access and Benefit Sharing scheme designed to manage potential global health emergencies.
"This framework is designed to ensure that when a nation contributes its samples, the resulting advantages – including medicines and cures – are shared equitably, not commercialised solely by those with the funds to create them."
Zimbabwe's reservations regarding the US deal "should not be misconstrued as opposition to America," he added.
"We welcome ongoing discussions with our American counterparts on how future collaboration might be arranged in a way that honours the sovereignty and dignity of each country."
Medical Community Response
The Zimbabwe College of Public Health Physicians (ZCPHP) expressed it acknowledged the government's concerns, but recommended that negotiations need to persist considering much of the country's Aids initiatives were funded by international support.
"Where specific concerns exist, including those relating to data governance or agreement terms, these can frequently be addressed through technical clarification and negotiated safeguards," it commented.
This impasse underscores the continuing tensions between receiving crucial foreign assistance and safeguarding a country's data in an increasingly interconnected world.